These results demonstrated that therapeutic CD47 antibodies may be effective against tumors with high EGFR expression when used alone or in combination with EGFR inhibitors, which maybe a novel treatment direction for malignant meningioma. This evidence concerns the gene CD47 and Anaplastic (Malignant) Meningioma.